VERA Reports $596.8M Cash, $1.69 EPS Loss, FDA Priority Review for Atacicept in IgAN, July 7 2026 PDUFA, Mid‑2026 Launch, $121M Q1 Net Loss
Vera Therapeutics, Inc. Class A Common Stock · PHARMACEUTICAL PREPARATIONS · Now $33.94
-4.3% in 7d after detection
Post-detection moves
1h
—
1d
+0.9%
3d
+2.3%
7d
-4.3%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS